Braftovi (encorafenib)

pCPA File Number: 21548
Negotiation Status:
Concluded with an LOI
Indication(s):
Braftovi in combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy,
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
PC0233
pCPA Engagement Letter Issued:
Negotiation Process Concluded: